Pre-treatment Elevated Platelet Count Associates with HER2 Overexpression and Prognosis in Patients with Breast Cancer |
Gu, Mei-Ling
(Department of Oncology, The First Affiliated Hospital of Liaoning Medical University)
Yuan, Cai-Jun (Department of Oncology, The First Affiliated Hospital of Liaoning Medical University) Liu, Xiao-Mei (Department of Oncology, The First Affiliated Hospital of Liaoning Medical University) Zhou, Yi-Chao (Department of Breast Surgery, The First Affiliated Hospital of Liaoning Medical University) Di, Shu-Huan (Department of Laboratory, The First Affiliated Hospital of Liaoning Medical University) Sun, Fei-Fei (Department of Pathology, The First Affiliated Hospital of Liaoning Medical University) Qu, Quan-Ying (Department of Epidemiology, Liaoning Medical University) |
1 | Bewick V, Cheek L, Ball J (2004). Statistics review 13: receiver operating characteristic curves. Crit Care, 8, 508-12. DOI |
2 | Buergy D, Wenz F, Groden C, Brockmann MA (2012). Tumorplatelet interaction in solid tumors. Int J Cancer, 130, 2747-60. DOI |
3 | Burstein HJ (2005). The distinctive nature of HER2-positive breast cancers. N Engl J Med, 353, 1652-4. DOI ScienceOn |
4 | Chen Y, Zhang L, Liu WX, Liu XY. (2015). Prognostic signifiance of preoperative anemia, leukocytosis and thrombocytosis in Chinese women with epithelial ovarian cancer. Asian Pac J Cancer Prev, 16, 933-9. DOI |
5 | Early Breast Cancer Trialists' Collaborative Group (EBCTCG), C Davies, J Godwin, R Gray, et al (2011). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet, 378, 771-84. DOI ScienceOn |
6 | Eltabbakh GH, Piver MS, Hempling RE, Recio FO, Intengen ME (1999). Clinical picture, response to therapy, and survival of women with diffuse malignant peritoneal mesothelioma. J Surg Oncol, 70, 6-12. DOI |
7 | Fang-Xuan Li, Li-Juan Wei, Huan Zhang, Shi-Xia Li, Jun-Tian Liu (2014). Significance of thrombocytosis in clinicopathologic characteristics and prognosis of gastric cancer. Asian Pac J Cancer Prev, 15, 6511-7. DOI |
8 | Foy KC, Miller MJ, Moldovan N (2012). Immunotherapy with HER-2 and VEGF peptide mimics plus metronomic paclitaxel causes superior antineoplastic effects in transplantable and transgenic mouse models of human breast cancer. Oncoimmunology, 1, 1004-16. DOI |
9 | Gastl G, Plante M, Finstad CL, et al (1993). High IL-6 levels in ascitic fluid correlate with reactive thrombocytosis in patients with epithelial ovarian cancer. Br J Haematol, 83, 433-41. DOI |
10 | Gerdes J, Schwab U, Lemke H, Stein H (1983). Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer, 31, 13-20. DOI |
11 | Gown AM (2008). Current issues in ER and HER-2 testing by IHC in breast cancer. Mod Pathol, 21, 8-15. DOI |
12 | Ikeda M, Furukawa H, Imamura H, et al (2002). Poor prognosis associated with thrombocytosis in patients with gastric cancer. Ann Surg Oncol, 9, 287-91. DOI |
13 | International Breast Cancer Study Group. Colleoni M, Gelber S, Goldhirsch A, et al (2006). Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph nodepositive breast cancer: international breast cancer study group trial 13-93. J Clin Oncol, 24, 1332-41. DOI |
14 | Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza GL (2001). HER2 (neu) signaling increases the rate ofhypoxia-inducible factor 1 (HIF-1) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol, 21, 3995-4004. DOI |
15 | Li Y, Miao LY, Xiao YL, Cai HR, Zhang DP (2014). Elevated platelets enhance cancer cell migration,promote hematogenous metastasis and associate with a poor prognosis in advanced non-small cell lung cancer cases. Asian Pac J Cancer Prev, 15, 139-43. DOI |
16 | Monreal M, Fernandez-Llamazares J, Pinol M, et al (1998). Platelet count and survival in patients with colorectal cancer-a preliminary study. Thromb Haemost, 79, 916-8. |
17 | Nakano T, Chahinian AP, Shinjo M, et al (1998). Interleukin 6 and its relationship to clinical parameters in patients with malignant pleural mesothelioma. Br J Cancer, 77, 907-12. DOI |
18 | Olesen LL, Thorshauge H (1988). Thrombocytosis in patients with malignant pleural mesothelioma. Cancer, 62, 1194-6. DOI |
19 | O'Byrne KJ, Dobbs N, Propper D, Smith K, Harris AL (1999). Vascular endothelial growth factor platelet counts, and prognosis in renal cancer. Lancet, 353, 1494-5. |
20 | O'Byrne KJ, Dobbs N, Propper D, Smith K, Harris AL (1999). Vascular endothelial growth factor platelet counts, and prognosis in renal cancer. Lancet, 353, 1494-5. |
21 | Pathmanathan N, Balleine RL, Jayasinghe UW, et al (2014). The prognostic value ofKi67 in systemically untreated patients with node-negative breast cancer. J Clin Pathol, 67, 222-8. DOI |
22 | Pedersen LM, Milman N (1996). Prognostic significance of thrombocytosis in patients with primary lung cancer. Eur Respir J, 9, 1826-30. DOI |
23 | Puhalla S, Brufsky A (2013). Treatment of HER2-positive breast cancer:looking backwards briefly. Lancet Oncol, 14, 1250-1. DOI |
24 | Ramirez A, Boulaiz H, Morata-Tarifa C, et al (2014). HER2-signaling pathway, JNK and ERKs kinases, and cancer stemlike cells are targets of Bozepinib. Onco Target, 5, 3590-606. |
25 | Stravodimou A,Voutsadakis IA (2013). Pretreatment Thrombocytosis As A Prognostic Factor In Metastatic Breast Cancer. Int J Breast Cancer, 2013, 289563-8. |
26 | Taucher S, Salat A, Gnant M, et al (2003). Impact of pretreatment thrombocytosis on survival in primary breast cancer. Thromb Haemost, 89, 1098-106. |
27 | Verheul HM, Hoekman K, Luykx-de Bakker S, et al (1997). Platelet:transporter ofvascular endothelial growth factor. Clin Cancer Res, 3, 2187-90. |
![]() |